Title |
A multi-arm multi-stage clinical trial design for binary outcomes with application to tuberculosis
|
---|---|
Published in |
BMC Medical Research Methodology, November 2013
|
DOI | 10.1186/1471-2288-13-139 |
Pubmed ID | |
Authors |
Daniel J Bratton, Patrick PJ Phillips, Mahesh KB Parmar |
Abstract |
Randomised controlled trials are becoming increasingly costly and time-consuming. In 2011, Royston and colleagues proposed a particular class of multi-arm multi-stage (MAMS) designs intended to speed up the evaluation of new treatments in phase II and III clinical trials. Their design, which controls the type I error rate and power for each pairwise comparison, discontinues randomisation to poorly performing arms at interim analyses if they fail to show a pre-specified level of benefit over the control arm. Arms in which randomisation is continued to the final stage of the trial are compared against the control on a definitive time-to-event outcome measure. To increase efficiency, interim comparisons can be made on an intermediate time-to-event outcome which is on the causal pathway to the definitive outcome. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 3 | 60% |
India | 1 | 20% |
United States | 1 | 20% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 4 | 80% |
Practitioners (doctors, other healthcare professionals) | 1 | 20% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 55 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 13 | 24% |
Student > Master | 6 | 11% |
Student > Ph. D. Student | 4 | 7% |
Professor | 3 | 5% |
Other | 3 | 5% |
Other | 8 | 15% |
Unknown | 18 | 33% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 12 | 22% |
Mathematics | 6 | 11% |
Agricultural and Biological Sciences | 3 | 5% |
Biochemistry, Genetics and Molecular Biology | 2 | 4% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 4% |
Other | 10 | 18% |
Unknown | 20 | 36% |